相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Infectious Diseases
Dora Buonfrate et al.
Summary: This study assessed the safety and efficacy of high-dose ivermectin in reducing viral load in individuals with early SARS-CoV-2 infection. The results showed that high-dose ivermectin was safe but did not reduce viral load effectively.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2022)
Article
Medicine, General & Internal
A. Jayk Bernal et al.
Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Jennifer Hammond et al.
Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
R. L. Gottlieb et al.
Summary: In symptomatic, nonhospitalized high-risk Covid-19 patients, a 3-day course of remdesivir significantly reduced the risk of hospitalization or death compared to placebo, with acceptable safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Cell Biology
William A. Fischer et al.
Summary: In a clinical trial, the safety, tolerability, and antiviral efficacy of molnupiravir were evaluated in unvaccinated individuals with confirmed SARS-CoV-2 infection. The study found that participants receiving high-dose molnupiravir had a shorter time to viral RNA clearance and a lower detection rate of infectious virus. Molnupiravir was well tolerated across all doses.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Public, Environmental & Occupational Health
Gilmar Reis et al.
Summary: Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early diagnosed COVID-19 reduced the need for hospitalisation defined as retention in a COVID-19 emergency setting or transfer to a tertiary hospital. The trial showed a higher probability of superiority (99.8%) surpassing the prespecified threshold of 97.6%.
LANCET GLOBAL HEALTH
(2022)
Article
Critical Care Medicine
Andrea Alemany et al.
Summary: This study aimed to evaluate whether early treatment with convalescent plasma reduces the risk of hospitalisation and decreases viral load among outpatients with COVID-19. The results showed that convalescent plasma did not prevent progression to severe illness or reduce viral load in this population.
LANCET RESPIRATORY MEDICINE
(2022)
Article
Immunology
Anca Streinu-Cercel et al.
Summary: The study found that Regdanvimab has some efficacy in patients with mild-to-moderate COVID-19, reducing the time to negative conversion of RT-qPCR results and the need for hospitalization and oxygen therapy.
OPEN FORUM INFECTIOUS DISEASES
(2022)
Review
Medicine, General & Internal
Anjum S. Kaka et al.
Summary: This review updates the evidence on the use of Remdesivir for adult patients with COVID-19. The findings suggest that Remdesivir may not significantly reduce mortality but increases the proportion of recovered patients. It may reduce time to clinical improvement and decrease serious adverse events, but may increase any adverse events.
ANNALS OF INTERNAL MEDICINE
(2022)
Article
Health Care Sciences & Services
Olivier Pierre et al.
Summary: The study assessed the sensitivity of two secondary electronic sources of COVID-19 studies, with the L.OVE platform showing better performance in identifying research reports.
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2022)
Article
Medicine, General & Internal
Anil Gupta et al.
Summary: The study showed that sotrovimab treatment significantly reduced the risk of all-cause hospitalization or death in nonhospitalized patients with mild to moderate COVID-19 and at risk of disease progression. Sotrovimab also decreased the risk of emergency department visits, hospitalization, or death, as well as the progression to severe or critical respiratory COVID-19. Adverse events were similar between the treatment and placebo groups.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Medicine, General & Internal
Tommy Nyberg et al.
Summary: The Omicron variant shows lower severity compared to Delta, especially in terms of hospital admission and death, with significant variations by age. Unvaccinated cases experience a larger reduction in intrinsic severity, while vaccinated cases experience reduced vaccine effectiveness. Booster vaccination with mRNA vaccines provides over 70% protection against hospitalization and death in breakthrough Omicron infections.
Article
Medicine, General & Internal
D. J. Sullivan et al.
Summary: This study evaluated the efficacy and safety of COVID-19 convalescent plasma in symptomatic adults and found that receiving convalescent plasma transfusion reduced the risk of hospitalization due to COVID-19-related reasons.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
G. Reis et al.
Summary: This study conducted in Brazil shows that the use of ivermectin treatment does not reduce the incidence of hospitalization or prolonged observation in the emergency department in outpatients with early diagnosis of Covid-19.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Medicine, General & Internal
Todd C. Lee et al.
Summary: This article summarized the effectiveness of fluvoxamine in the outpatient management of COVID-19, showing a significant association with reduced hospitalization risk under different assumptions, which could be a promising management option.
Article
Medicine, General & Internal
Steven H. Woolf et al.
Summary: This study confirms that the US experienced a significant decrease in life expectancy between 2019 and 2020, a trend not observed in other high-income countries. The decrease in life expectancy was more pronounced among Hispanic and non-Hispanic Black populations, reflecting the long-standing health inequities resulting from exclusionary policies and systemic racism. Addressing the systemic causes of US health disadvantage and persistent racial and ethnic inequities is crucial.
Article
Biochemistry & Molecular Biology
Aekkachai Tuekprakhon et al.
Summary: The Omicron variant of SARS-CoV-2 has rapidly spread globally and has evolved into different sublineages, with BA.4 and BA.5 dominating in South Africa. These sublineages show reduced neutralization by vaccine and naturally immune serum, indicating the possibility of repeat Omicron infections.
Letter
Infectious Diseases
Prerna Arora et al.
LANCET INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Qian Wang et al.
Summary: SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 have become dominant in the United States and South Africa, raising concerns about their ability to evade neutralizing antibodies and compromise the efficacy of COVID-19 vaccines and therapeutic monoclonals. A systematic antigenic analysis reveals that BA.2.12.1 and BA.4/5 have different levels of resistance to antibodies, with BA.2.12.1 being modestly resistant and BA.4/5 being substantially resistant. Certain mutations in the spike protein facilitate antibody escape, but compromise the spike affinity for the viral receptor. Only bebtelovimab retains full potency against both subvariants.
Article
Respiratory System
Alireza Mirahmadizadeh et al.
Summary: This study found that single-dose and double-dose ivermectin were not superior to placebo in preventing hospitalization and improving the clinical course of mild COVID-19 patients.
Article
Critical Care Medicine
Hugh Montgomery et al.
Summary: This study evaluated the safety and efficacy of tixagevimab-cilgavimab in preventing severe COVID-19 or death in non-hospitalized adults. The results showed that a single dose of tixagevimab-cilgavimab significantly reduced the risk of progression to severe COVID-19 or death, with favorable safety.
LANCET RESPIRATORY MEDICINE
(2022)
Article
Medicine, General & Internal
Mohammad Sadegh Rezai et al.
Summary: The study results indicate that ivermectin as a treatment for COVID-19 did not have a significant effect on improving clinical symptoms or reducing hospital admissions and mortality rates.
FRONTIERS IN MEDICINE
(2022)
Article
Infectious Diseases
Asaf Biber et al.
Summary: This study assessed the antiviral activity of ivermectin in nonhospitalized COVID-19 patients. The results showed that the ivermectin group had lower viral loads and fewer viable cultures, indicating its potential to reduce transmission.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Review
Medicine, General & Internal
Maria Popp et al.
Summary: The evidence on the efficacy and safety of ivermectin for treating COVID-19 is conflicting. Results suggest uncertainty in the effectiveness of ivermectin for treating severe cases and limited effects for mild cases.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Article
Medicine, General & Internal
Jean-Francois Rossignol et al.
Summary: There is an urgent need for treatments of mild or moderate COVID-19 in an outpatient setting. This study found that oral nitazoxanide is safe and effective in treating these patients, but further large-scale trials are needed to confirm its efficacy.
Review
Medicine, General & Internal
Mirko Griesel et al.
Summary: This study assessed the effectiveness and safety of inhaled corticosteroids in the treatment of COVID-19. The findings suggest that inhaled corticosteroids may reduce the risk of hospital admission or death and improve symptom resolution in people with mild COVID-19. However, there is low certainty evidence regarding the impact on mortality, serious adverse events, and infections. Further research is needed to determine the effects of inhaled corticosteroids on these outcomes.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Article
Infectious Diseases
Hyeonji Seo et al.
Summary: This study found no significant differences in clinical deterioration between patients treated with fluvoxamine and placebo among adult patients with symptomatic COVID-19 admitted to the CTC. Factors such as age, fever, and pneumonia may be independent risk factors for clinical deterioration.
INFECTION AND CHEMOTHERAPY
(2022)
Review
Medicine, General & Internal
Stefanie Reis et al.
Summary: Nirmatrelvir/ritonavir may reduce mortality and hospitalization in outpatient settings with mild COVID-19, but may increase some treatment-related adverse events. Ethnicity may influence treatment effectiveness in the equity aspect. However, there is currently no available evidence for nirmatrelvir/ritonavir in treating hospitalized patients or preventing SARS-CoV-2 infection.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Article
Health Care Sciences & Services
Chantelle Garritty et al.
Summary: The study aims to develop guidance to support the conduct of rapid reviews, with 26 recommendations presented based on survey results. These recommendations will help synthesize evidence for urgent health issues, but the guidance will need to be updated as new evaluations for some RR methods are conducted due to the current lack of available evidence.
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2021)
Article
Respiratory System
Patricia R. M. Rocco et al.
Summary: In patients with mild COVID-19, there was no difference in symptom resolution between nitazoxanide and placebo groups after 5 days of treatment, but early nitazoxanide therapy significantly reduced viral load.
EUROPEAN RESPIRATORY JOURNAL
(2021)
Article
Medicine, General & Internal
R. Libster et al.
Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Eduardo Lopez-Medina et al.
Summary: The study found that a 5-day course of ivermectin did not significantly improve the time to resolution of symptoms in adults with mild COVID-19, and does not support its use for treatment of mild COVID-19. Larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
D. M. Weinreich et al.
Summary: REGEN-COV reduced the risk of Covid-19-related hospitalization or death, resolved symptoms, and reduced the SARS-CoV-2 viral load more rapidly than the placebo.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Nicole Ezer et al.
Summary: The study aimed to determine if inhaled and intranasal ciclesonide were better than placebo in reducing respiratory symptoms in adult outpatients with covid-19. Results showed that there were no significant differences in symptom resolution between the intervention group receiving ciclesonide and the control group.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Review
Medicine, General & Internal
Matthew J. Page et al.
Summary: The methods and results of systematic reviews should be reported in sufficient detail to allow users to assess trustworthiness. PRISMA 2020 aims to improve the transparency and completeness of systematic review reporting, in hopes of guiding more accurate and transparent reporting.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Medicine, General & Internal
Gilmar Reis et al.
Summary: This randomized clinical trial did not find any significant benefit in reducing COVID-19-associated hospitalization or other secondary clinical outcomes with hydroxychloroquine or lopinavir-ritonavir among high-risk outpatients.
Article
Medicine, General & Internal
Amir Qaseem et al.
Summary: The Scientific Medical Policy Committee (SMPC) of the American College of Physicians (ACP) aims to provide evidence-based clinical advice through rapid systematic review, use of the GRADE method, and strict policies on disclosure of interests, to address timely key questions for decision-making.
ANNALS OF INTERNAL MEDICINE
(2021)
Article
Infectious Diseases
Julio Vallejos et al.
Summary: This study conducted in Argentina randomized non-hospitalized individuals with early COVID-19 into ivermectin and placebo groups, finding that ivermectin did not significantly prevent hospitalization, but patients in the ivermectin group required invasive mechanical ventilatory support earlier compared to the placebo group. No significant differences were observed in any of the other secondary outcomes.
BMC INFECTIOUS DISEASES
(2021)
Article
Pharmacology & Pharmacy
Jin Yong Kim et al.
Summary: CT-P59, a SARS-CoV-2 neutralizing monoclonal antibody, showed potential in reducing viral titers, shortening recovery time, and improving clinical symptoms based on two studies.
CLINICAL THERAPEUTICS
(2021)
Article
Medicine, General & Internal
Catherine E. Oldenburg et al.
Summary: The study investigated the efficacy of azithromycin in outpatients with SARS-CoV-2 infection, and found that a single dose of azithromycin did not increase the likelihood of being symptom free at day 14 compared to placebo. These findings suggest that routine use of azithromycin for outpatient SARS-CoV-2 infection may not be necessary.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Frederick K. Korley et al.
Summary: This study showed that administering Covid-19 convalescent plasma to high-risk outpatients within 1 week after symptom onset did not prevent disease progression.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Psychology
Quentin F. Gronau et al.
Summary: Meta-analysis is a predominant approach for quantitatively synthesizing studies, with Bayesian model-averaged meta-analysis offering an alternative method that combines different Bayesian models to address key questions in a principled way. This approach avoids the need to choose between fixed-effect or random-effects models and takes into account model uncertainty.
ADVANCES IN METHODS AND PRACTICES IN PSYCHOLOGICAL SCIENCE
(2021)
Review
Medicine, General & Internal
Vanessa Piechotta et al.
Summary: Convalescent plasma and hyperimmune immunoglobulin are being investigated as potential therapies for COVID-19, with a living systematic review approach being used to assess their effectiveness and safety. The current evidence suggests that convalescent plasma does not reduce all-cause mortality or significantly improve clinical outcomes for individuals with moderate to severe disease, but its impact on other outcomes remains uncertain. Further ongoing studies are needed to determine the full potential of these interventions.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Article
Medicine, General & Internal
Carlos Chaccour et al.
Summary: The study found that early administration of a single 400 mcg/kg dose of ivermectin did not significantly reduce the transmission of SARS-CoV-2, but it did markedly alleviate anosmia/hyposmia, reduce cough, and show a tendency to lower viral loads and IgG titers.
Review
Medicine, General & Internal
Carina Wagner et al.
Summary: Systemic corticosteroids may slightly reduce all-cause mortality in people with COVID-19, with low-certainty evidence on outcomes like ventilator-free days. More high-quality studies are needed to determine treatment effects.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Review
Medicine, General & Internal
Bhagteshwar Singh et al.
Summary: The study evaluated the effects of chloroquine and hydroxychloroquine in treating and preventing COVID-19. Results showed that these drugs did not significantly impact the death rate or virus clearance time in infected patients, while they may increase the risk of adverse events.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Review
Medicine, General & Internal
Maria Popp et al.
Summary: Antibiotics with potential antiviral and anti-inflammatory properties are being investigated in clinical trials for treatment of COVID-19, but current evidence does not conclusively support their efficacy or safety. More research is needed to verify whether antibiotics, including azithromycin, are beneficial for COVID-19 patients, particularly in the context of antimicrobial resistance.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Editorial Material
Medicine, General & Internal
Isabelle Boutron et al.
ANNALS OF INTERNAL MEDICINE
(2020)
Article
Medicine, General & Internal
Eric J. Lenze et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2020)
Article
Medicine, General & Internal
Ali S. Omrani et al.
Article
Computer Science, Interdisciplinary Applications
Christian Roever
JOURNAL OF STATISTICAL SOFTWARE
(2020)
Article
Medicine, General & Internal
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL
(2019)
Article
Psychology, Mathematical
John K. Kruschke et al.
PSYCHONOMIC BULLETIN & REVIEW
(2018)
Article
Health Care Sciences & Services
Howard Balshem et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2011)
Article
Computer Science, Interdisciplinary Applications
Wolfgang Viechtbauer
JOURNAL OF STATISTICAL SOFTWARE
(2010)
